Efficacy and safety of nintedanib for progressive fibrosing interstitial diseases in single center cohort study
Not Applicable
Recruiting
- Conditions
- progressive fibrosing interstitial lung diseases
- Registration Number
- JPRN-UMIN000042254
- Lead Sponsor
- Japanese Red Cross Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have been treated with nintedanib 2) Patients requiring treatment with anticoagulants and high-dose antiplatelet drugs 3) Patients with a history of acute exacerbations within 6 months 4) Complications of poor control 5) Patients who cannot perform respiratory function test 6) Pregnant patients 7) Other patients who the doctor in charge deems inappropriate for safe administration
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method